AstraZeneca funded Non-clinical PhD Studentship (Fixed Term) in Improved 2A peptides for co-translational separation of a polyprotein

University of Cambridge

Cambridge

On-site

GBP 21,000 - 26,000

Full time

14 days+

A complete application in a minute

Tailored resume and cover letter, ready to send.

Get past ATS filters

Job summary

University of Cambridge invites applications for a four-year PhD studentship starting 1 October 2027. The project is a collaboration between the Department of Pathology (University of Cambridge) and the AstraZeneca Discovery Centre, with joint supervision from Prof. Andrew Firth and Dr Giovanni Ciotta.

Work across both sites to probe peptide-bond skipping for protein engineering. The project emphasises molecular biology, ribosome profiling, and potential bioinformatics and structural biology

Responsibilities

  • Collaborate across the UCam and AstraZeneca sites to deliver the PhD project.
  • Apply molecular biology techniques to investigate 2A sequences and ribosome skipping, with potential bioinformatic skill development.

Job description

Applications are invited for a 4-year PhD studentship starting on 1 October 2027 and based in the Department of Pathology, University of Cambridge, and the AstraZeneca Discovery Centre at Cambridge. The student will be working on a collaborative project jointly supervised by Prof. Andrew Firth at the University of Cambridge and Dr Giovanni Ciotta at AstraZeneca and will have the opportunity to work across the two sites. The project focuses on manipulating peptide-bond skipping sequences to aid protein engineering.

2A peptides mediate co-translational separation of a polyprotein via a mechanism known as "ribosome skipping" or "StopGo". These ~20 amino acid peptides adopt an unusual conformation within the translating ribosome that prevents peptide bond formation at a specific site but instead promotes release of the nascent peptide followed by continuation of translation. These sequences have proved to be exceptionally useful in biotechnology because they allow the introduction of all components of a pathway or multi-subunit complex in a single step, with stable stoichiometric co-expression from a single promoter. However, 2A peptides have some caveats - including ribosome drop-off, ribosome pausing/stalling, and some amount of separation failure - which constrain their functional utility. We have identified new classes of 2A sequences, some of which have improved properties compared to traditional 2A peptides. This PhD project will contribute to our work investigating these new 2A sequences and optimising them for biotechnological applications.

The UCam team has expertise in molecular biology including ribosome profiling, ribosome structure and function, cell biology, cryo-electron microscopy, and bioinformatics. The AZ team has expertise in cell therapy, CRISPR/Cas9 technologies, and viral vectors. The PhD project will focus on molecular biology techniques but there will also be opportunity for bioinformatic skill development and there may be scope to obtain structural biology experience. At the AstraZeneca site, the student will focus on implementing optimised sequences in specific biotechnological applications, e.g. in cell therapy.

From £23,805 p.a.

Get your free, confidential resume review.

or drag and drop your file here.

Similar jobs

Similar jobs worth comparing

PhD: Optimizing 2A Peptides for Polyprotein Split
PhD: Optimizing 2A Peptides for Polyprotein Split

University of Cambridge • Cambridge

On-site
GBP 21,000 - 26,000
AstraZeneca Non-Clinical PhD Studentship in Next-generation TPD for Oncology: Harnessing Ubiquitin-independent Pathways
AstraZeneca Non-Clinical PhD Studentship in Next-generation TPD for Oncology: Harnessing Ubiquitin-independent Pathways

University of Cambridge • Cambridge

On-site
GBP 18,000 - 21,000
Scientist II/ Sr Scientist - Protein Mass Spectrometry
Scientist II/ Sr Scientist - Protein Mass Spectrometry

Abzena • Cambridge

On-site
GBP 35,000 - 40,000
Associate Principal Scientist – Upstream Process Development (Temporary Maternity Cover)
Associate Principal Scientist – Upstream Process Development (Temporary Maternity Cover)

AstraZeneca plc • Cambridge

On-site
GBP 70,000 - 100,000
AstraZeneca-Funded Non-Clinical PhD Studentship (Fixed Term): Physics-Guided Representation Learning for Drug Discovery
AstraZeneca-Funded Non-Clinical PhD Studentship (Fixed Term): Physics-Guided Representation Learning for Drug Discovery

University of Cambridge • Cambridge

On-site
GBP 19,000 - 20,000
Stipend provided
Tuition fees at UK/Home rate
International candidates eligible with
+1
Scientist Bioconjugation
Scientist Bioconjugation

ASTRAZENECA UK LIMITED • Cambridge

On-site
GBP 42,000 - 62,000
Senior Scientist Bioconjugation
Senior Scientist Bioconjugation

AstraZeneca plc • Cambridge

On-site
GBP 70,000 - 90,000
Postdoctoral Fellow, Multiple Myeloma Immuno-Oncology, Oncology Bioscience
Postdoctoral Fellow, Multiple Myeloma Immuno-Oncology, Oncology Bioscience

AstraZeneca plc • Cambridge

On-site
GBP 76,000 - 91,000
PG Funding: PhD Studentship - Process Industries: Net Zero CDT: Sustainable, High-resolution Purification of GLP-1 Peptide Therapeutics
PG Funding: PhD Studentship - Process Industries: Net Zero CDT: Sustainable, High-resolution Purification of GLP-1 Peptide Therapeutics

Newcastle University • Newcastle upon Tyne

On-site
GBP 20,000 - 24,000
Living allowance £21,805
4-year duration
PhD Studentship: New pharmacological tools for targeting P2X receptors in cancer
PhD Studentship: New pharmacological tools for targeting P2X receptors in cancer

University of East Anglia • Norwich

On-site
GBP 20,000 - 24,000
Funding for UK applicants
Annual stipend £21,805